Related Experiment Videos
Economic evaluation of vaccination
1Centre for Evaluation of Vaccination, University of Antwerp, Belgium.
Pharmacoeconomics
|December 9, 1995
Summary
Economic evaluations of vaccinations help allocate healthcare budgets efficiently. Cost-effectiveness analysis compares vaccination strategies, with influenza vaccination for the elderly showing favorable results compared to others.
Area of Science:
- Health Economics
- Preventive Medicine
- Vaccinology
Background:
- Rising healthcare expenditures necessitate efficient resource allocation.
- Economic evaluations are crucial tools for optimizing healthcare spending.
- Vaccination strategies require cost-benefit assessments to ensure value.
Purpose of the Study:
- To explore the role of economic evaluations in healthcare decision-making.
- To compare the cost-effectiveness of various vaccination strategies.
- To assess the economic viability of influenza vaccination in the elderly.
Main Methods:
- Economic evaluation techniques including cost-effectiveness, cost-utility, and cost-benefit analyses.
- Comparison of vaccination strategies against a non-intervention baseline.
- Calculation of costs (direct and indirect) and health gains (natural units, quality-adjusted life-years, monetary units).
Main Results:
- Influenza vaccination for the elderly appears economically favorable (approx. $US650 per life-year gained).
- Cost-effectiveness ratios vary significantly across different vaccinations, from $US720 for Hepatitis B to $US190,000 for Haemophilus influenzae type b per life-year gained.
- Divergent results in economic evaluations are common due to methodological differences and country-specific parameters.
Conclusions:
- Economic evaluations provide valuable insights for healthcare budget allocation.
- Influenza vaccination for the elderly is a cost-effective intervention.
- Standardization of economic evaluation methods is needed for reliable comparisons across studies and interventions.